title: Time course of recovery and complications of HELLP syndrome with two different treatments: heparin or dexamethasone.
abstract: HELLP syndrome is a severe complication of pregnancy characterized by microangiopathic hemolytic anemia, hepatic dysfunction and thrombocytopenia. Though delivery is the ultimate therapeutic option, medical treatments, including the use of heparin or corticosteroids, have been employed in the attempt to improve maternal prognosis. The aim of this retrospective study was to compare the time course of recovery and the incidence of complications in women with HELLP syndrome receiving either heparin or dexamethasone. Between January 1990 and December 1998, 32 patients with HELLP syndrome were cared for at the Institute of Obstetrics and Gynecology of the University of Florence: 20 patients were treated with heparin, administered subcutaneously at a dose of 5000 IU every 12 h, whereas 12 women received dexamethasone, administered intravenously at a dose of 10 mg every 12 h. Categorical data were evaluated with chi-square and Fisher's exact test; continuous data were analyzed with Mann-Whitney U test; P < .05 was considered significant. In the subgroup treated with heparin the incidence of disseminated intravascular coagulation (DIC) (P < .02), the number of patients requiring blood transfusion (P < .05) and the length of stay at the Intensive Care Unit (ICU) (P < .04) were significantly increased as compared with the subgroup receiving dexamethasone; in this latter subgroup, significantly higher platelet count and hematocrit values, and significantly lower levels of lactate dehydrogenase (LDH) could be documented starting from day 2 after delivery. The results of our investigation suggest that the use of dexamethasone in patients with HELLP syndrome is associated with faster regression and lower incidence of complications in comparison to heparin.
authors.affiliation: Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Viale Morgagni, 85, I-50134, Florence, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Mecacci
authors.forename: L
authors.initials: L
authors.lastname: Carignani
authors.forename: R
authors.initials: R
authors.lastname: Cioni
authors.forename: E
authors.initials: E
authors.lastname: Parretti
authors.forename: M
authors.initials: M
authors.lastname: Mignosa
authors.forename: A
authors.initials: A
authors.lastname: Piccioli
authors.forename: G
authors.initials: G
authors.lastname: Scarselli
authors.forename: G
authors.initials: G
authors.lastname: Mello
mesh_terms: D000328:Adult; D001803:Blood Transfusion; D003907:Dexamethasone / Q000008:administration & dosage / Q000592:standards; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D005260:Female; D017359:HELLP Syndrome / Q000150:complications* / Q000188:drug therapy*; D006400:Hematocrit; D006493:Heparin / Q000008:administration & dosage / Q000592:standards; D006760:Hospitalization; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D010976:Platelet Count; D011247:Pregnancy; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003907:Dexamethasone; D006493:Heparin; D007770:L-Lactate Dehydrogenase